Singular Genomics highlights G4X milestones at AGBT

Singular Genomics (OMIC) announced key development milestones for its G4X Spatial Sequencer at the Advances in Genome Biology and Technology conference in Marco Island, Florida.The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform’s real-world potential. Singular plans to expand its early access program to a few more sites in Q2. Meanwhile, pre-orders for the G4X are now open, and initial shipments are on track for June 2025. Researchers wishing to start generating multiomic data can use Singular’s technology access services in the meantime. At AGBT, Singular Genomics presented data demonstrating the G4X platform’s robust integrated multiomic performance. Immune-oncology-focused lung, kidney, colon, and breast panels showed high sensitivity, specificity, and reproducibility in FFPE samples, providing comprehensive spatial insights into cancerous and healthy tissues. Building on these data, Singular showcased advanced 3D multi-omic reconstruction and niche detection from 10 serial renal cell carcinoma FFPE sections, over 6.2 million cells, and 438 million transcripts-all from a single G4X flow cell.